Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-09-25 | 2024-06 | 0 | N/A | N/A | N/A |
2024-05-15 | 2024-03 | 0 | -0.52 | N/A | N/A |
2024-02-14 | 2023-12 | 0 | -0.04 | N/A | N/A |
2023-11-14 | 2023-09 | 0 | -1.48 | N/A | N/A |
2023-09-27 | 2023-06 | 0 | 0.16 | N/A | N/A |
2023-05-11 | 2023-03 | 0 | -1.93 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-08 | Maxim Group | Upgrade | Buy | |
2023-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-04-15 | CANTRELL GARY V. | Director | 204.09K | Stock Award(Grant) |
2023-06-13 | DISBROW JOSHUA R. | Chief Executive Officer | 71.59K | Purchase |
2023-08-10 | DOCKERY CARL C | Director | 8.94K | Stock Award(Grant) |
2021-04-07 | HECHT BETH P | Director | 9.05K | Stock Award(Grant) |
2023-08-15 | JAIN ABHINAV | Director | 8.00K | Stock Award(Grant) |
2023-08-10 | LIU VIVIAN H | Director | 1.84K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Nantahala Capital Management, LLC | 1.09M | 1.74M | 19.65% |
2023-06-29 | Stonepine Capital Management, LLC | 472.37K | 755.79K | 8.54% |
2023-06-29 | Renaissance Technologies, LLC | 57.32K | 91.72K | 1.04% |
2023-06-29 | Blackrock Inc. | 24.06K | 38.49K | 0.44% |
2023-06-29 | Acadian Asset Management. LLC | 22.54K | 36.06K | 0.41% |
2023-06-29 | Prudential Financial, Inc. | 19.58K | 31.32K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 9.99K | 15.99K | 0.18% |
2023-05-30 | Fidelity Extended Market Index Fund | 8.71K | 14.55K | 0.16% |
2023-05-30 | Fidelity Series Total Market Index Fund | 1.59K | 2.66K | 0.03% |
2023-05-30 | Fidelity Total Market Index Fund | 1.59K | 2.65K | 0.03% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 1.27K | 2.15K | 0.02% |
Split | Date |
---|---|
1 : 20 | 2023-01-06 |
1 : 10 | 2020-12-09 |
1 : 20 | 2018-08-13 |
1 : 20 | 2017-08-29 |
1 : 12 | 2016-07-01 |
82 : 1000 | 2015-06-10 |
-
Lot of BULL in here just day traders will hurt us selling to low. Bouncing the .10 cent thing I see over stocks.
-
Need know worries about 2 that is easy to forecast and see. 2 by noon is easy. If this stock is not over 2 by noon we should worry some. I see $2.15 today before press release or higher.
-
Waz up AYTU . Stocktwits kick me out @Lifeontheline for i dont’t fucking know why ?
Good to be back on AYTU i told ya il be back . Bought 12k shares yesterday to push it up at 1.69
Cmon JoSh bring us some big doo -
Wow busy time and good sign as almost 11m in trades before market. Definitely hitting 2 dollars this morning and then we will see how it goes today.
I’m in for the after hours and camped hard.
SHOW ME THE MONEY!
SHOW ME THR MONEY!Good luck and may we all haves delightful public news event.
-
Yes I think the kit will get FDA approval.
This is pure politics and political money in my book.Since the test was not American made it has not received approval. Hopefully AYTU figures out how to make the test in the USA. That will be big news!
-
Lol funny
Good luck Shorts hopefully you dont get a big bill -
Hoping everyone sets the limit to five dollars are more the rest of the week.
-
-
-
Nice cup and handle chart $$$$$
-
Im back after couples of weeks . Bar code misse me so much lol .
-
-
That’s a Big Article from Canada
Just posted today and using AYTUNICE ARTICLE
-
Buy buy buy buy
-
-
$GNUS it is running look out after market special coming as the push hits over a dollar.
Good luck and check it out
-
-
$MVIS want say anymore going up and moving fast before power hour.
-
$OBSV
Don’t mis this run. Lots of upside potential.ObsEva SA (NASDAQ:OBSV) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders will be ecstatic, with their stake up 30% over the past week following ObsEva SA‘s (NASDAQ:OBSV) latest quarterly results. Revenues came in 113% better than analyst models expected, at US$4.0kwhile statutory losses per share were US$0.48, in line with forecasts. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
-
Robyn sounds Q’d. But so correct. Soo much going on right now n world so few are aware of
-
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
accesswire.com • -
Best Penny Stocks? 4 Hot Stocks With News This Week
pennystocks.com • -
Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript
seekingalpha.com •